Guardant Health Inc. shares reached a fresh 52-week high of $176.68 on Thursday, continuing a remarkable rally that has seen the stock surge more than 216% over the past year.
The advance followed the company's second-quarter results, which showed revenue of $335 million, representing 44% year-over-year growth and topping analyst estimates. The quarter posted a 7% sales upside, driven by strong volume growth in its Shield and G360 product lines.
Several Wall Street firms raised or reaffirmed their price targets following the report. TD Cowen increased its target to $210 from a prior level, maintaining a Buy rating. Bernstein also set a $210 price target with an Outperform rating.
Stifel raised its price target to $180 and kept a Buy rating. Piper Sandler reiterated an Overweight rating with a $193 target, citing expanded commercial coverage and approval of G360 Liquid CDx.
Rothschild Redburn initiated coverage with a Buy rating and a $203 price target, highlighting the potential of Shield, the company's FDA-approved colorectal cancer screening blood test.
The results underscore growing clinical and commercial traction for Guardant's liquid biopsy platform. Shield, used for early-stage colorectal cancer detection, continues to gain adoption, while G360 Liquid CDx received approval for broader genomic profiling applications.
The stock's 52-week peak comes amid a sector-wide recalibration toward precision oncology diagnostics, with investors rewarding companies showing measurable revenue growth and expanding regulatory approvals.
